Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design
暂无分享,去创建一个
Shibo Jiang | S. Heck | Shibo Jiang | Yuxian He | S. Lustigman | Sara Lustigman | Yuxian He | Jingjing Li | Susanne Heck | Jingjing Li
[1] Jingxin Cao,et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.
[2] Shuhan Sun,et al. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. , 2005, DNA and cell biology.
[3] Kwok-Hung Chan,et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] Jonathan H. Epstein,et al. Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.
[5] Gary J. Nabel,et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.
[6] Chengsheng Zhang,et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.
[7] Shibo Jiang,et al. SARS vaccine development. , 2005, Emerging infectious diseases.
[8] X. L. Liu,et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.
[9] E. Marshall,et al. Medicine. Caution urged on SARS vaccines. , 2004, Science.
[10] Guo-Ping Zhao,et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] W. Hong,et al. Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents , 2005, Journal of Virology.
[12] A. Abbott,et al. Virus detectives seek source of SARS in China's wild animals , 2003, Nature.
[13] D. Dimitrov,et al. A model of the ACE2 structure and function as a SARS-CoV receptor , 2003, Biochemical and Biophysical Research Communications.
[14] Sung Keun Kang,et al. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. , 2004, Science.
[15] M. Enserink. One Year After Outbreak, SARS Virus Yields Some Secrets , 2004, Science.
[16] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[17] Christian Drosten,et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.
[18] R. Hodges,et al. Structural Characterization of the SARS-Coronavirus Spike S Fusion Protein Core , 2004, Journal of Biological Chemistry.
[19] J. Lepault,et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] D. Ho,et al. Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.
[21] R. Proulx,et al. Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.
[22] A. Danchin,et al. The Severe Acute Respiratory Syndrome , 2003 .
[23] Xiaolei Yin,et al. Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing Antibodies , 2004, Journal of Virology.
[24] Shibo Jiang,et al. Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines , 2004, The Journal of Immunology.
[25] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[26] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[27] D. Dimitrov. The Secret Life of ACE2 as a Receptor for the SARS Virus , 2003, Cell.
[28] K. Holmes,et al. SARS-associated coronavirus. , 2003, The New England journal of medicine.
[29] A. Debnath,et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.
[30] Kwanyee Leung,et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] B. Moss,et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[32] Wenhui Li,et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Murphy,et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[34] E. Marshall,et al. Caution Urged on SARS Vaccines , 2004, Science.
[35] M. Buchmeier,et al. Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.
[36] Jens H. Kuhn,et al. Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2 , 2004, Journal of Virology.
[37] S. Pöhlmann,et al. Cellular entry of the SARS coronavirus , 2004, Trends in Microbiology.
[38] H. Doerr,et al. Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.
[39] Shibo Jiang,et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.
[40] Gary J. Nabel,et al. Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization , 2005, Journal of Virology.
[41] L. Anderson,et al. Laboratory Diagnosis of Four Recent Sporadic Cases of Community-acquired SARS, Guangdong Province, China , 2004, Emerging infectious diseases.
[42] B. Murphy,et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.
[43] S. Qiu,et al. An Exposed Domain in the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Induces Neutralizing Antibodies , 2004, Journal of Virology.
[44] W. Thomas,et al. Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with Receptor , 2004, Journal of Virology.
[45] Obi L. Griffith,et al. The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.
[46] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[47] Y. Guan,et al. Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.
[48] A. Carfi,et al. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[49] Shibo Jiang,et al. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry , 2004, Biochemical and Biophysical Research Communications.
[50] Shibo Jiang,et al. Vaccine design for severe acute respiratory syndrome coronavirus. , 2005, Viral immunology.
[51] Shibo Jiang,et al. Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies , 2005, The Journal of Immunology.
[52] Baoan Yang,et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.
[53] Guoping Zhao,et al. Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.
[54] Wenhui Li,et al. A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.
[55] T. Kuiken,et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.